Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1994 Target Snapshot

Mineralocorticoid receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,446Compounds
276Assays
23Approved Drugs
1,658.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Mineralocorticoid receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P08235. Start with cardiovascular disease, then reuse UniProt P08235 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cardiovascular disease, then reuse UniProt P08235 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 8 linked drugs
Open source guide
Disease program
cardiovascular disease

Mineralocorticoid receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include BALCINRENONE, CANRENOATE POTASSIUM, CANRENONE, EPLERENONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 8 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mineralocorticoid receptor as ChEMBL target CHEMBL1994, mapped to UniProt P08235. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mineralocorticoid receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1994
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08235
Mineralocorticoid receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mineralocorticoid receptor is the right protein anchor across sources, using UniProt P08235 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cardiovascular disease is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMineralocorticoid receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP08235
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMineralocorticoid receptor
UniProt AccessionP08235
Component TypeProtein
Sequence Length984 aa

Mineralocorticoid receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Mineralocorticoid receptor, mapped to UniProt P08235. Sequence length is 984 aa.

Mapped IDP08235
Review nameMineralocorticoid receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Mineralocorticoid receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cardiovascular disease
8 linked drugs · 8 direct · 8 efficacy
Linked drugBALCINRENONE
Linked drugCANRENOATE POTASSIUM
Linked drugCANRENONE
Linked drugEPLERENONE
Approved-linked Approved
chronic kidney disease
5 linked drugs · 5 direct · 5 efficacy
Linked drugBALCINRENONE
Linked drugEPLERENONE
Linked drugFINERENONE
Linked drugLY2623091
Approved-linked Approved
essential hypertension
4 linked drugs · 4 direct · 4 efficacy
Linked drugEPLERENONE
Linked drugLY2623091
Linked drugSPIRONOLACTONE
Linked drugXL550
Approved-linked Approved
heart failure
4 linked drugs · 4 direct · 4 efficacy
Linked drugBALCINRENONE
Linked drugEPLERENONE
Linked drugFINERENONE
Linked drugSPIRONOLACTONE
Approved-linked Approved
hypertension
4 linked drugs · 4 direct · 4 efficacy
Linked drugEPLERENONE
Linked drugFELODIPINE
Linked drugSPIRONOLACTONE
Linked drugXL550
Approved-linked Approved
type 2 diabetes mellitus
4 linked drugs · 4 direct · 4 efficacy
Linked drugEPLERENONE
Linked drugFELODIPINE
Linked drugFINERENONE
Linked drugPF-03882845
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include BALCINRENONE, CANRENOATE POTASSIUM, CANRENONE, EPLERENONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecardiovascular disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

23
Approved
5
Phase III
9
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC501,289.0
KI276.0
EC5086.0
KD7.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4532472 10.3 EC50 0.05012 Preclinical
CHEMBL4095917 10.1 Ki 0.08 Preclinical
CHEMBL273453 9.74 EC50 0.18 Clinical
CHEMBL4086416 9.64 Ki 0.23 Preclinical
CHEMBL131 9.54 Ki 0.29 Approved
CHEMBL273453 9.52 IC50 0.305 Clinical
CHEMBL235206 9.5 Ki 0.319 Preclinical
CHEMBL4572476 9.5 Ki 0.3162 Preclinical
CHEMBL4088896 9.48 Ki 0.33 Clinical
CHEMBL3120319 9.47 Ki 0.342 Preclinical
Distribution

pChEMBL Value Distribution

73
5.0
221
5.5
261
6.0
242
6.5
205
7.0
117
7.5
71
8.0
35
8.5
23
9.0
6
9.5
pChEMBL
Approved Drugs

Approved Drugs

FINERENONE
CHEMBL2181927
Approved 2021
Properties Compare Identifier
FLUTICASONE FUROATE
CHEMBL1676
Approved 2007
Properties Compare Identifier
EPLERENONE
CHEMBL1095097
Approved 2002
Properties Compare Identifier
MIFEPRISTONE
CHEMBL1276308
Approved 2000
Properties Compare Identifier
BUDESONIDE
CHEMBL1370
Approved 1994
Properties Compare Identifier
FLUTICASONE PROPIONATE
CHEMBL1473
Approved 1990
Properties Compare Identifier
HYDROCORTISONE BUTYRATE
CHEMBL1683
Approved 1982
Properties Compare Identifier
PROGESTERONE
CHEMBL103
Approved 1976
Properties Compare Identifier
SPIRONOLACTONE
CHEMBL1393
Approved 1960
Properties Compare Identifier
DEXAMETHASONE
CHEMBL384467
Approved 1958
Properties Compare Identifier
PREDNISOLONE
CHEMBL131
Approved 1955
Properties Compare Identifier
HYDROCORTISONE
CHEMBL389621
Approved 1952
Properties Compare Identifier
Assay Landscape

Assay Landscape

276
Total Assays
892
Tested Compounds
3
Assay Types
Binding — 185 assays, 892 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 87 348 6.8
single protein format 86 410 6.7
assay format 12 134 6.8
Functional — 89 assays, 187 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 47 23 6.0
cell-based format 42 164 6.6
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine